Eli Lilly executive on crucial tirzepatide data: "It is a very exciting time"

Before the turn of the year, Eli Lilly will receive the phase III results for the drug tirzepatide, meant to beat the best products in the top-selling GLP-1 segment on the diabetes market. Jamie Croaning, who leads the development of the drug at Eli Lilly, speaks of a paradigm shift.

The US pharmaceutical company Eli Lilly is Novo Nordisk's greatest competitor on the diabetes market.

Before New Year's, the bar will be raised for how well a diabetes drug can perform when Eli Lilly displays the first phase III results from the future hope tirzepatide.

That is, at least, the hope that Eli Lilly's Global Brand Development Leader James Croaning has. He is in charge of the development of tirzepatide in Eli Lilly's diabetes business.

Read this article for free

Register with your E-mail.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

Related articles